Ionis Pharmaceuticals Inc (NASDAQ:IONS) was the target of unusually large options trading on Thursday. Investors purchased 2,727 put options on the stock. This represents an increase of approximately 1,180% compared to the average daily volume of 213 put options.
Several brokerages recently issued reports on IONS. Needham & Company LLC reiterated a “buy” rating and set a $64.00 price target on shares of Ionis Pharmaceuticals in a report on Tuesday, October 17th. Zacks Investment Research upgraded Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $68.00 price target for the company in a report on Tuesday, October 17th. Stifel Nicolaus reiterated a “hold” rating and set a $50.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 13th. Goldman Sachs Group reiterated a “sell” rating and set a $30.00 price target on shares of Ionis Pharmaceuticals in a report on Friday, October 6th. Finally, BMO Capital Markets upped their price target on Ionis Pharmaceuticals from $64.00 to $65.00 and gave the stock an “outperform” rating in a report on Wednesday, November 8th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $50.76.
Ionis Pharmaceuticals (NASDAQ IONS) opened at $53.22 on Friday. The stock has a market capitalization of $6,635.38, a price-to-earnings ratio of 354.82 and a beta of 2.86. The company has a debt-to-equity ratio of 1.50, a current ratio of 6.25 and a quick ratio of 6.21. Ionis Pharmaceuticals has a 12 month low of $37.26 and a 12 month high of $65.51.
In related news, SVP C Frank Bennett sold 12,250 shares of the company’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total transaction of $796,250.00. Following the completion of the sale, the senior vice president now owns 27,291 shares in the company, valued at $1,773,915. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO B Lynne Parshall sold 16,118 shares of the company’s stock in a transaction on Wednesday, October 18th. The stock was sold at an average price of $65.00, for a total value of $1,047,670.00. Following the sale, the chief operating officer now owns 33,526 shares of the company’s stock, valued at approximately $2,179,190. The disclosure for this sale can be found here. Insiders have sold 102,781 shares of company stock valued at $5,733,330 in the last quarter. 2.13% of the stock is currently owned by corporate insiders.
A number of large investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its stake in Ionis Pharmaceuticals by 4.4% in the 2nd quarter. Vanguard Group Inc. now owns 9,855,160 shares of the company’s stock valued at $501,332,000 after purchasing an additional 417,364 shares during the period. BlackRock Inc. grew its stake in Ionis Pharmaceuticals by 4.0% in the 2nd quarter. BlackRock Inc. now owns 6,823,987 shares of the company’s stock valued at $347,135,000 after purchasing an additional 264,179 shares during the period. American Century Companies Inc. lifted its position in shares of Ionis Pharmaceuticals by 33.0% during the 3rd quarter. American Century Companies Inc. now owns 1,144,526 shares of the company’s stock valued at $58,027,000 after buying an additional 284,266 shares during the last quarter. First Trust Advisors LP lifted its position in shares of Ionis Pharmaceuticals by 40.2% during the 3rd quarter. First Trust Advisors LP now owns 982,344 shares of the company’s stock valued at $49,805,000 after buying an additional 281,733 shares during the last quarter. Finally, Northern Trust Corp lifted its position in shares of Ionis Pharmaceuticals by 7.8% during the 2nd quarter. Northern Trust Corp now owns 621,816 shares of the company’s stock valued at $31,631,000 after buying an additional 44,750 shares during the last quarter. Hedge funds and other institutional investors own 91.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Ionis Pharmaceuticals Target of Unusually Large Options Trading (IONS)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/01/14/ionis-pharmaceuticals-target-of-unusually-large-options-trading-ions-2.html.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners.
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.